Insulet | PODD - Cost Of Sales


Insulet reported $232.7M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Align Technology USD 303.5M 60.47M Mar/2026
AtriCure USD 31.94M 3.22M Mar/2026
Avanos Medical USD 88M 6.9M Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Becton, Dickinson and Co. USD 2.56B 281M Mar/2026
Boston Scientific USD 1.83B 8M Mar/2026
Cardinal Health USD 58.54B 4.82B Mar/2026
Cooper Companies USD 393.8M 17M Mar/2026
Dexcom USD 441.6M 25.3M Mar/2026
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Globus Medical USD 263.59M 26.88M Mar/2026
ICU Medical USD 337.72M 1.61M Dec/2025
Inogen USD 39.59M 1.27M Sep/2024
Insulet USD 232.7M 17.5M Mar/2026
Integra LifeSciences USD 178.71M 14.73M Mar/2026
J&J USD 8.07B 103M Mar/2026
Masimo USD 152.8M 12.4M Mar/2026
Medtronic USD 3.8B 195M Mar/2026
Merit Medical Systems USD 197.08M 1.5M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Solventum Corp USD 911M 60M Mar/2026
Stryker USD 2.36B 325M Mar/2026
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teleflex USD 240.84M 20.7M Mar/2026
West Pharmaceutical Services USD 548.5M 47.4M Mar/2026
Zimmer Biomet Holdings USD 738.3M 231.8M Mar/2026